NO20072964L - Fremgangsmåte for fremstilling av trans-(-)-¿9-tetrahydrocannabinolsammensetning eller en trans-(+)-¿9-tetrahydrokannabinolsammensetning samt fremgangsmåte for fremstilling av krystallinsk (±)-¿9-tetrahydrokannabinol - Google Patents

Fremgangsmåte for fremstilling av trans-(-)-¿9-tetrahydrocannabinolsammensetning eller en trans-(+)-¿9-tetrahydrokannabinolsammensetning samt fremgangsmåte for fremstilling av krystallinsk (±)-¿9-tetrahydrokannabinol

Info

Publication number
NO20072964L
NO20072964L NO20072964A NO20072964A NO20072964L NO 20072964 L NO20072964 L NO 20072964L NO 20072964 A NO20072964 A NO 20072964A NO 20072964 A NO20072964 A NO 20072964A NO 20072964 L NO20072964 L NO 20072964L
Authority
NO
Norway
Prior art keywords
tetrahydrocannabinol
trans
preparation
composition
crystalline
Prior art date
Application number
NO20072964A
Other languages
English (en)
Other versions
NO331831B1 (no
Inventor
Boris Pertsikov
Boris Tishin
Arie Gutman
Gennady A Nevich
Igor Rukhman
Irina Fedotev
Ram Khanolkar
Marina Etinger
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072964(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20072964L publication Critical patent/NO20072964L/no
Publication of NO331831B1 publication Critical patent/NO331831B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
NO20072964A 2004-11-22 2007-06-11 Fremgangsmate for fremstilling av trans-(-)-¿9-tetrahydrocannabinolsammensetning eller en trans-(+)-¿9-tetrahydrokannabinolsammensetning samt fremgangsmate for fremstilling av krystallinsk (±)-¿9-tetrahydrokannabinol NO331831B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63055604P 2004-11-22 2004-11-22
PCT/EP2005/012378 WO2006053766A1 (en) 2004-11-22 2005-11-18 Methods for purifying trans-(-)-δ9-tetrahydrocannabinol and trans-(+)-δ9-tetrahydrocannabinol

Publications (2)

Publication Number Publication Date
NO20072964L true NO20072964L (no) 2007-08-17
NO331831B1 NO331831B1 (no) 2012-04-16

Family

ID=35789123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072964A NO331831B1 (no) 2004-11-22 2007-06-11 Fremgangsmate for fremstilling av trans-(-)-¿9-tetrahydrocannabinolsammensetning eller en trans-(+)-¿9-tetrahydrokannabinolsammensetning samt fremgangsmate for fremstilling av krystallinsk (±)-¿9-tetrahydrokannabinol

Country Status (31)

Country Link
US (6) US8383842B2 (no)
EP (3) EP2289509B1 (no)
JP (3) JP4995728B2 (no)
KR (1) KR100919719B1 (no)
CN (2) CN102151259A (no)
AR (1) AR054989A1 (no)
AT (1) ATE500824T1 (no)
AU (2) AU2005305944B2 (no)
BR (1) BRPI0519803A2 (no)
CA (2) CA2921590C (no)
CY (1) CY1111471T1 (no)
DE (1) DE602005026852D1 (no)
DK (3) DK2289509T3 (no)
EA (1) EA012299B1 (no)
ES (3) ES2556802T3 (no)
HK (3) HK1109058A1 (no)
HR (3) HRP20110385T1 (no)
HU (2) HUE025904T2 (no)
IL (1) IL183306A (no)
ME (2) ME02306B (no)
MX (1) MX2007006104A (no)
NO (1) NO331831B1 (no)
NZ (1) NZ556038A (no)
PL (3) PL2289509T3 (no)
PT (2) PT2289509E (no)
RS (3) RS54338B1 (no)
SI (3) SI2289509T1 (no)
TW (2) TWI369203B (no)
UA (1) UA88491C2 (no)
WO (1) WO2006053766A1 (no)
ZA (1) ZA200706837B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CN101316832A (zh) 2005-09-29 2008-12-03 Amr科技公司 δ-9-四氢大麻酚的生成方法
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB0702895D0 (en) * 2007-02-14 2007-03-28 Resolution Chemicals Ltd Delta 9 tetrahydrocannabinol derivatives
GB0703284D0 (en) * 2007-02-20 2007-03-28 Resolution Chemicals Ltd Delta 9 - tetrahydrocannabinol processing
CA2751741C (en) * 2008-02-06 2018-07-10 Mallinckrodt Inc. Process for the preparation of (-) -delta 9-tetrahydrocannabinol
US10624859B2 (en) 2012-08-20 2020-04-21 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
US10155708B2 (en) * 2015-01-22 2018-12-18 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
US11034639B2 (en) 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
US10207198B2 (en) 2015-01-22 2019-02-19 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
CN106268657A (zh) * 2015-05-14 2017-01-04 株式会社大赛璐 光学异构体用分离剂
US10059683B2 (en) * 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
CN109153661B (zh) * 2016-05-13 2023-01-17 西姆莱斯有限公司 用于纯化大麻素化合物的方法
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN106810426B (zh) * 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
US11213558B2 (en) 2017-05-17 2022-01-04 Orochem Technologies, Inc. CBX extraction-isolation process
US10189762B1 (en) * 2017-07-07 2019-01-29 Orochem Technologies, Inc. Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves
EP3676238A1 (en) * 2017-09-01 2020-07-08 Pureform Global, Inc. Synthetic cannabidiol compositions and methods of making the same
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
US11192870B2 (en) 2018-03-07 2021-12-07 Socati Technologies—Oregon, Llc Continuous isolation of cannabidiol and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
CN112105606A (zh) * 2018-03-07 2020-12-18 索卡蒂科技俄勒冈有限公司 大麻素的连续分离以及大麻素向δ8-四氢大麻酚和δ9-四氢大麻酚的转化
US11851415B2 (en) 2018-03-07 2023-12-26 Cleen Technology Inc. Continuous isolation of cannabidiol and cannabinoids and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol
EP3814315A1 (en) * 2018-06-28 2021-05-05 Symrise AG Synthesis of (+)-cannabinoids and their therapeutic effects
CA3073093A1 (en) 2018-08-03 2020-02-06 Biomass Oil Separation Solutions, Llc Processes and apparatus for extraction of substances and enriched extracts from plant material
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20210380514A1 (en) 2018-10-31 2021-12-09 Enantia S.L. Solid compositions of cocrystals of cannabinoids
EP3653596A1 (en) 2018-11-14 2020-05-20 Indena S.p.A. Continuous flow synthesis of cannabidiol
CN109734554B (zh) * 2019-02-25 2021-11-23 江苏暨明医药科技有限公司 一种反式-薄荷基-2,8-二烯-1-醇的合成工艺
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
WO2020248062A1 (en) * 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for cannabinoid isomerization
US10799546B1 (en) 2019-07-26 2020-10-13 Biomass Oil Separation Solutions, Llc Modular, integrated process and apparatus for extracting, refining and remediating active substances from plant material
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
WO2021081138A1 (en) * 2019-10-21 2021-04-29 Esolate Ltd Compositions comprising superfine compounds and production thereof
GB2588457B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB2588455B (en) * 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
US20220340507A1 (en) 2020-03-12 2022-10-27 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Process for the synthesis of cannabidiol and intermediates thereof
CN113336705B (zh) * 2021-08-09 2021-12-10 中国农业科学院农产品加工研究所 一种大麻二酚-2-咪唑-1-甲酸酯及其应用
WO2024028516A1 (en) 2022-08-05 2024-02-08 Salud & Semillas, S.L. CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl3 * 6H2O AS CATALYST
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法
CN115784836A (zh) * 2022-12-08 2023-03-14 南京康立瑞生物科技有限公司 一种高选择性的制备反式-薄荷基-2,8-二烯-1-醇的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507885A (en) 1966-03-25 1970-04-21 Hoffmann La Roche 3-alkyl-6h-dibenzo(b,d)pyrans
CH481911A (de) 1967-05-19 1969-11-30 Theodor Dr Petrzilka Verfahren zur Herstellung von tricyclischen Verbindungen
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
US4025516A (en) 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4381399A (en) 1981-12-21 1983-04-26 Aerojet-General Corporation Purification of tetrahydrodibenzo[b,d]pyrans from crude synthetic mixtures
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US6703418B2 (en) 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6730519B2 (en) 1998-10-26 2004-05-04 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
US20020039795A1 (en) 1998-10-26 2002-04-04 Elsohly Et Al Method of preparing delta-9-tetrahydrocannabinol
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
FI990915A0 (fi) 1999-04-23 1999-04-23 Orion Yhtymae Oyj Jauheinhalaattori
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6747058B1 (en) 1999-08-20 2004-06-08 Unimed Pharmaceuticals, Inc. Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
GB2368061B (en) 2000-10-20 2005-05-11 Gw Pharmaceuticals Ltd Dose dispensing apparatus
KR100968128B1 (ko) 2000-10-30 2010-07-06 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
EP1409473A2 (en) 2001-03-07 2004-04-21 Websar Innovations Inc. CONVERSION OF CBD TO $g(D)?8 -THC AND $g(D)?9 -THC
US20030050334A1 (en) 2001-04-30 2003-03-13 Murty Ram B. Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CN100999513A (zh) * 2002-02-01 2007-07-18 分析化学品有限公司 △9四氢大麻酚的制备
WO2003070506A1 (fr) 2002-02-21 2003-08-28 Biel Timothee Dispositif d'entraînement pour vehicules a moteur, notamment avec propulsion hybride
UA79281C2 (en) 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CA2770448C (en) 2002-11-12 2014-03-25 Prairie Plant Systems Inc. Cannabinoid esters
US20040229939A1 (en) 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
EP1696929A4 (en) 2003-11-05 2010-02-24 Unimed Pharmaceuticals Inc DELTA-9-THC COMPOSITIONS AND METHODS OF TREATING MULTIPLE SCLEROSIS-RELATED SYMPTOMS
GB0329635D0 (en) * 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
EP1773801A1 (de) 2004-07-19 2007-04-18 Cilag Ltd. Verfahren zur gewinnung von reinem tetrahydrocannabinol
GB0425445D0 (en) 2004-11-18 2004-12-22 Smithkline Beecham Corp Novel compositions
TWI369203B (en) * 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
PT2176208E (pt) 2007-07-30 2015-05-11 Zynerba Pharmaceuticals Inc Pró-fármacos de canabidiol, composições compreendendo pró- fármacos de canabidiol e métodos de utilização dos mesmos
US8642645B2 (en) * 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEVIN, S. et al. Resolution of chiral cannabinoids on amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase: effects of structural features and mobile phase additives. Journal of Chromotography A. 1993, vol 654, s. 53-64., Dated: 01.01.0001 *

Also Published As

Publication number Publication date
HUE027197T2 (en) 2016-10-28
DE602005026852D1 (de) 2011-04-21
PL2356987T3 (pl) 2016-09-30
HRP20151301T1 (hr) 2016-01-01
IL183306A0 (en) 2007-09-20
NZ556038A (en) 2009-12-24
CN101076329B (zh) 2011-08-10
EP2356987A1 (en) 2011-08-17
DK1824475T3 (da) 2011-06-06
AU2005305944A1 (en) 2006-05-26
TW201302722A (zh) 2013-01-16
HK1109058A1 (en) 2008-05-30
ME02403B (me) 2016-09-20
EA200701123A1 (ru) 2007-12-28
CA2921590A1 (en) 2006-05-26
SI2356987T1 (sl) 2016-04-29
US20150126596A1 (en) 2015-05-07
KR100919719B1 (ko) 2009-10-06
EP2289509A2 (en) 2011-03-02
RS54338B1 (en) 2016-02-29
US8383842B2 (en) 2013-02-26
US20090298930A1 (en) 2009-12-03
BRPI0519803A2 (pt) 2009-03-17
CY1111471T1 (el) 2015-08-05
CA2587957A1 (en) 2006-05-26
US9744151B2 (en) 2017-08-29
UA88491C2 (ru) 2009-10-26
TWI369203B (en) 2012-08-01
AU2010200227A1 (en) 2010-02-11
EP2289509B1 (en) 2015-10-14
US20130171259A1 (en) 2013-07-04
EP1824475B1 (en) 2011-03-09
CA2921590C (en) 2019-09-24
US20160184261A1 (en) 2016-06-30
US9278083B2 (en) 2016-03-08
PL2289509T3 (pl) 2016-04-29
TW200633695A (en) 2006-10-01
PL1824475T3 (pl) 2011-09-30
CN102151259A (zh) 2011-08-17
SI2289509T1 (sl) 2016-01-29
ES2362288T3 (es) 2011-06-30
JP4995728B2 (ja) 2012-08-08
US20160199344A1 (en) 2016-07-14
NO331831B1 (no) 2012-04-16
JP2008101000A (ja) 2008-05-01
EP2356987B1 (en) 2016-01-06
PT1824475E (pt) 2011-06-01
AU2005305944B2 (en) 2010-03-04
ATE500824T1 (de) 2011-03-15
JP2008520608A (ja) 2008-06-19
HK1154796A1 (en) 2012-05-04
ME02306B (me) 2016-06-20
HUE025904T2 (en) 2016-05-30
SI1824475T1 (sl) 2011-06-30
MX2007006104A (es) 2007-07-11
WO2006053766A1 (en) 2006-05-26
CA2587957C (en) 2016-05-03
HRP20160300T1 (hr) 2016-04-22
ZA200706837B (en) 2008-04-30
JP5048448B2 (ja) 2012-10-17
RS54537B1 (en) 2016-06-30
TWI436991B (zh) 2014-05-11
DK2356987T3 (en) 2016-03-21
JP2012180350A (ja) 2012-09-20
DK2289509T3 (en) 2015-11-23
US9675581B2 (en) 2017-06-13
WO2006053766A8 (en) 2006-12-14
CN101076329A (zh) 2007-11-21
ES2566480T3 (es) 2016-04-13
HRP20110385T1 (hr) 2011-06-30
EP2289509A3 (en) 2011-08-10
PT2289509E (pt) 2015-12-23
KR20070086529A (ko) 2007-08-27
IL183306A (en) 2012-06-28
HK1159500A1 (en) 2012-08-03
AR054989A1 (es) 2007-08-01
EA012299B1 (ru) 2009-08-28
EP1824475A1 (en) 2007-08-29
US20160184260A1 (en) 2016-06-30
US8937097B2 (en) 2015-01-20
RS51706B (en) 2011-10-31
ES2556802T3 (es) 2016-01-20

Similar Documents

Publication Publication Date Title
NO20072964L (no) Fremgangsmåte for fremstilling av trans-(-)-¿9-tetrahydrocannabinolsammensetning eller en trans-(+)-¿9-tetrahydrokannabinolsammensetning samt fremgangsmåte for fremstilling av krystallinsk (±)-¿9-tetrahydrokannabinol
IL183840A0 (en) Compositions and methods for reducing the transmissivity of illnesses
NO20051281D0 (no) Sammensetning for anrikning av naeringsmidler
IL183102A0 (en) Betulin derivatives and pharmaceutical compositions containing the same
DE602005020076D1 (de) Herstellung von TNFR-Fc
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
IL177168A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL190249A0 (en) Deazapurine derivatives and pharmaceutical compositions containing the same
IL176538A0 (en) Steroid derivatives and pharmaceutical compositions containing the same
IL183583A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
IL188941A0 (en) Pyrazinolyguanidine derivatives and pharmaceutical compositions containing the same
IL186738A0 (en) Pyrizole derivatives and pharmaceutical compositions containing the same
IL183919A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
IL189782A0 (en) Sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL221323A0 (en) 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same
BRPI0717699A2 (pt) "composição e seus processos de preparação, uso de uma composição e uso coméstico de uma composição!
IL184996A0 (en) Dihydroimidazothiazole derivatives and pharmaceutical compositions containing the same
IL181730A0 (en) Benzodiazinone derivatives and pharmaceutical compositions containing the same
IL177498A0 (en) Difluoroethoxy -substituted hydroxy-6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
HK1151466A1 (en) Oral pharamaceutical composition of glycyrrhizin or its salts and the preparation method thereof
IL189172A0 (en) Cercosporamide derivatives and pharmaceutical compositions containing the same
IL177497A0 (en) Isoamido-substituted hydroxy-6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
BRPI0610156A2 (pt) forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
CL2008000047A1 (es) Compuestos derivados de sulfonamida; procedimiento de preparacion; composicion farmaceutica que contiene a dichos compuestos; y su uso en el tratamiento y profilaxis de aterotrombosis y asma.
EP1929881A4 (en) EMULSION COMPOSITION AND PROCESS FOR PREPARING THE SAME